PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research[1].
in vivo
PD-L1-IN-2 (compound 11c) (i.p.; 25/50 mg/kg; once a day; 16 days) decreases the tumor sizes with an inhibition rate of 45% at 45 mg/kg, and the average tumor weight of the 50 mg/kg groups is significantly lower than that of the PBS group[1].
Animal Model:
C57BL/6 mice with subcutaneous MC38 tumors[1]
Dosage:
25/50 mg/kg
Administration:
i.p.; 25/50 mg/kg; once a day; 16 days
Result:
Suppressed MC38 tumor growth in vivo.
References
[1] Pan-Pan Fu, et al. Bioactivity-Driven Synthesis of the Marine Natural Product Naamidine J and Its Derivatives as Potential Tumor Immunological Agents by Inhibiting Programmed Death-Ligand 1. J Med Chem. 2023 Apr 27;66(8):5427-5438. DOI:10.1021/acs.jmedchem.2c01702
